Biosyntia

Biosyntia, a biotech startup founded in 2012 and headquartered in Denmark, has attracted significant attention with its latest €11.50M Series B investment on 06 July 2022. The company's prowess lies in its synthetic biology and metabolic engineering capabilities, allowing for the rapid development of biocatalysts through its patent-pending high-throughput screening technology. This cutting-edge approach enables Biosyntia to tailor processes based on biocatalysis, facilitating the production of complex chemical compounds through fermentation. By partnering with manufacturers of fine chemical compounds, Biosyntia aims to promote sustainable manufacturing processes to reduce environmental impact. The backing of renowned investors such as Novo Holdings, Sofinnova Partners, ECBF reflects the potential seen in Biosyntia's technology and its impact on the fields of biopharma, biotechnology, and manufacturing. Situated in the vibrant startup incubator Symbion in Copenhagen, Biosyntia's dedication to innovative, sustainable solutions positions it as a promising player in the industry.